Trial Profile
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 05 Dec 2016 Primary endpoint (6-month progression free survival) has been met, according to the results published in the Gynecologic Oncology
- 05 Dec 2016 Results published in the Gynecologic Oncology
- 22 Sep 2015 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.